Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03563183
Registration number
NCT03563183
Ethics application status
Date submitted
4/06/2018
Date registered
20/06/2018
Date last updated
30/04/2020
Titles & IDs
Public title
A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022
Query!
Scientific title
Observational Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 and HZ Efficacy, Immunogenicity and Safety of HZ/su by Frailty Status
Query!
Secondary ID [1]
0
0
204878
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Herpes Zoster
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Other interventions - Encoding of data collected in Zoster 006 and Zoster 022 studies
Overall Group - Adults aged =50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
Other interventions: Encoding of data collected in Zoster 006 and Zoster 022 studies
Not applicable (disease epidemiology study)
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Subjects by Frailty Status, at Baseline
Query!
Assessment method [1]
0
0
Frailty status was measured in relation to the accumulation of deficits using a Frailty Index (FI) adapted from the model proposed by Mitnitski et al. \[Mitnitski, 2001\]. The different aspects of frailty composing the FI were assessed through the medical history and components of the Short Form 36 Questionnaire (SF-36) and EuroQol (EQ)-5D questionnaires recorded pre-vaccination Dose 1 (in the study ZOSTER-006\[NCT01165177\] and ZOSTER-022\[NCT01165229\]).
If the FI was less than or equal to 0.08, the subject was classified as Non-Frail. If the score was greater than 0.08 but less than or equal to 0.25, the subject was classified as pre-frail. If the score was greater than 0.25, the subject was classified as Frail. Subjects without a FI score were classified as unknown.
Query!
Timepoint [1]
0
0
At Baseline (Month 0)
Query!
Secondary outcome [1]
0
0
Distribution of Short Form 36 (SF-36) Questionnaire Scale Scores, by Country
Query!
Assessment method [1]
0
0
The mean and standard deviation of the SF-36 Questionnaire scale scores are presented for each time point. The SF-36 is a multi-purpose health survey with 36 questions underlying the construction of 8 scales \[Ware, 2001\]: Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH).
All but one of the 36 items (self-reported health transition) are used to score the eight SF-36 scales. Each item is used in scoring only one scale. Scale scores are constructed following the summated ratings and standardized SF-36 scoring algorithms. The SF-36 scores range from 0 to 100, with high scores indicating high levels of functioning/quality of life.
Query!
Timepoint [1]
0
0
At Month 0, 14, 26 and 38
Query!
Secondary outcome [2]
0
0
Distribution of EuroQol (EQ)-5D Questionnaire Scale Scores, by Country
Query!
Assessment method [2]
0
0
The EQ-5D questionnaire is a generic measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 possible responses (No symptoms, Moderate symptoms, Extreme symptoms). The 5 items are then combined to generate health profiles that are subsequently converted to a continuous single index utility score using a one to one matching. Country or region-specific value sets are used for the score conversion. The scores range from less than 0 (where 0 is the value of a health state equivalent to dead) to 1 (the value of full health), with higher scores indicating higher health utility.
The EQ-5D also contains a visual analogue scale (VAS). The VAS records the respondent's self-rated health on a vertical scale, ranging from 0(worst imaginable health state) to 100(best imaginable health state).
Query!
Timepoint [2]
0
0
At Month 0, 14, 26 and 38
Query!
Secondary outcome [3]
0
0
Incidence Rate (Per 1000 Person-years) of Confirmed Herpes Zoster (HZ) Cases, by Frailty Status
Query!
Assessment method [3]
0
0
Incidence rate (IR) of confirmed Herpes zoster (HZ) cases with 95% Confidence Interval (CI) calculated as the number of cases per 1000 person-years : numerator = number of confirmed HZ cases reported during the follow-up (FU) period at risk; denominator = total Person-years at risk, i.e. sum of FU periods at risk expressed in years until first confirmed HZ cases or occurrence of treatment for relapse. A suspected HZ case defined as (1) new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or vesicular rash suggestive of Varicella Zoster Virus (VZV) infection regardless of the distribution, and no alternative diagnosis; or (2) clinical presentation and specific laboratory findings suggestive of VZV infection in the absence of HZ or VZV rash. A suspected case of HZ was confirmed either by PCR or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
Query!
Timepoint [3]
0
0
During the entire study period (3 to 5 year period following Day 0)
Query!
Secondary outcome [4]
0
0
Herpes Zoster Burden of Illness Score, by Frailty Status
Query!
Assessment method [4]
0
0
Zoster Brief Pain Inventory (ZBPI) Burden of Illness (BOI) score was calculated as the sum of the ZBPI worst pain scores for all subjects in the group divided by the total follow-up time (Person-years). HZ Burden of Illness score for subjects was calculated from the Zoster Brief Pain Inventory (ZBPI), for each confirmed HZ cases responding to the "worst pain" question in both ZOSTER-006 and ZOSTER-022, and defined as the area under the curve of confirmed HZ-associated pain plotted against time during the 182-day period after the onset of the case. Subjects who developed HZ presented "burden-of-illness" scores ranging from 0 up to, theoretically, 1820. A score of 0 is recorded for subjects in whom HZ did not develop during the study period. Subjects who had a confirmed Zoster episode but who did not have at least 1 ZBPI assessment were excluded from the analysis.
Query!
Timepoint [4]
0
0
During the entire study period (3 to 5 year period following Day 0)
Query!
Secondary outcome [5]
0
0
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Frailty Status
Query!
Assessment method [5]
0
0
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Query!
Timepoint [5]
0
0
Within 7 days (Days 0-6) after each vaccination
Query!
Secondary outcome [6]
0
0
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Frailty Status
Query!
Assessment method [6]
0
0
Assessed solicited general symptoms were, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and gastro-intestinal (GI) symptoms(nausea, vomiting, diarrhoea and/or abdominal pain) Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Query!
Timepoint [6]
0
0
Within 7 days (Days 0-6) after each vaccination
Query!
Secondary outcome [7]
0
0
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs), by Frailty Status
Query!
Assessment method [7]
0
0
An unsolicited AE covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Query!
Timepoint [7]
0
0
Within 30 days (Days 0 - 29) after each vaccination
Query!
Secondary outcome [8]
0
0
Number of Subjects With Any and Related Serious Adverse Events (SAEs), by Frailty Status
Query!
Assessment method [8]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs were those considered vaccine-related by the investigator.
Query!
Timepoint [8]
0
0
From Month 0 to Month 14
Query!
Secondary outcome [9]
0
0
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine, by Frailty Status
Query!
Assessment method [9]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAEs throughout the entire study period by frailty status were reported for SAEs considered related to study participation or to a concurrent GSK medication/vaccine.
Query!
Timepoint [9]
0
0
During the entire study period (3 to 5 year period following Day 0)
Query!
Secondary outcome [10]
0
0
Number of Subjects With Any Fatal Serious Adverse Events (SAEs), by Frailty Status
Query!
Assessment method [10]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death.
Query!
Timepoint [10]
0
0
During the entire study period (3 to 5 year period following Day 0)
Query!
Secondary outcome [11]
0
0
Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs), by Frailty Status
Query!
Assessment method [11]
0
0
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as related to the vaccination.
Query!
Timepoint [11]
0
0
During the entire study period (3 to 5 year period following Day 0)
Query!
Secondary outcome [12]
0
0
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Query!
Assessment method [12]
0
0
Anti-gE Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 97 milli-international units (mIU)/mL.
Query!
Timepoint [12]
0
0
Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38
Query!
Secondary outcome [13]
0
0
Anti-Varicella Zoster Virus (Anti-VZV) Antibody (Ab) Concentrations, by Frailty Status, in a Subset of Subjects
Query!
Assessment method [13]
0
0
Anti-VZV Ab concentrations as determined by Enzyme-linked Immunosorbent Assay (ELISA), in a subset of subjects. The assay cut-off is 25 mIU/mL.
Query!
Timepoint [13]
0
0
Pre-vaccination at Month 0, and post second dose at Months 3, 14, 26 and 38
Query!
Eligibility
Key inclusion criteria
* All subjects who participated in the Zoster 006 and Zoster 022 trials.
* Subjects who died or were lost to follow-up during ZOSTER-006 and ZOSTER-022 will be considered for enrolment in ZOSTER-064 and their data/questionnaires up to that point will be used.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subjects who were excluded from all analyses from ZOSTER-006 and ZOSTER-022. This will include any subject eliminated following deviations from GCP compliance.
* Subjects who developed a suspected HZ case during ZOSTER-006 and ZOSTER-022 (since their QoL questionnaires were encoded in the eCRF for ZOSTER-006 and ZOSTER-022).
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Retrospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/06/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/04/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
26976
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Maroubra
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Umina
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Westmead
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Wollongong
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Sherwood
Query!
Recruitment postcode(s) [1]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [2]
0
0
2257 - Umina
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
2522 - Wollongong
Query!
Recruitment postcode(s) [5]
0
0
4075 - Sherwood
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Idaho
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Utah
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
Minas Gerais
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Paraná
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Curitiba/PR
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
São Paulo
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
British Columbia
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Newfoundland and Labrador
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Nova Scotia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Ontario
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Quebec
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Hradec Kralove
Query!
Country [26]
0
0
Estonia
Query!
State/province [26]
0
0
Tallinn
Query!
Country [27]
0
0
Estonia
Query!
State/province [27]
0
0
Tartu
Query!
Country [28]
0
0
Finland
Query!
State/province [28]
0
0
Tampereen Yliopisto
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Angers
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Cherbourg
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Château Gontier
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Clermont-Ferrand
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Laval
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Montrevault
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Muret
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Murs-Erigne
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Nantes cedex 2
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Rosiers-d'Egletons
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Saint Cyr sur Loire
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Segré
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Tours
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Baden-Wuerttemberg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Bayern
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hessen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Niedersachsen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Nordrhein-Westfalen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Rheinland-Pfalz
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Sachsen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Schleswig-Holstein
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hamburg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Magdeburg
Query!
Country [53]
0
0
Hong Kong
Query!
State/province [53]
0
0
Kwun Tong
Query!
Country [54]
0
0
Hong Kong
Query!
State/province [54]
0
0
Shatin
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Abruzzo
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Lazio
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Liguria
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Lombardia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Piemonte
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Fukuoka
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Kanagawa
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Tokyo
Query!
Country [63]
0
0
Korea, Republic of
Query!
State/province [63]
0
0
Gangwon-do
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Gyeonggi-do
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Incheon
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Seoul
Query!
Country [67]
0
0
Mexico
Query!
State/province [67]
0
0
Jalisco
Query!
Country [68]
0
0
Mexico
Query!
State/province [68]
0
0
Durango
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Alcover( Tarragona)
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Balenyà (Barcelona)
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Centelles (Barcelona)
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
La Roca Del Valles (Barcelona)
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Majadahonda( Madrid
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Marid
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Peralada( Girona)
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Valencia
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Vic/ Barcelona
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Borås
Query!
Country [81]
0
0
Sweden
Query!
State/province [81]
0
0
Eskilstuna
Query!
Country [82]
0
0
Sweden
Query!
State/province [82]
0
0
Göteborg
Query!
Country [83]
0
0
Sweden
Query!
State/province [83]
0
0
Jönköping
Query!
Country [84]
0
0
Sweden
Query!
State/province [84]
0
0
Karlskrona
Query!
Country [85]
0
0
Sweden
Query!
State/province [85]
0
0
Linköping
Query!
Country [86]
0
0
Sweden
Query!
State/province [86]
0
0
Malmö
Query!
Country [87]
0
0
Sweden
Query!
State/province [87]
0
0
Uppsala
Query!
Country [88]
0
0
Sweden
Query!
State/province [88]
0
0
Vällingby
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Örebro
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Taichung
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Taipei
Query!
Country [92]
0
0
Taiwan
Query!
State/province [92]
0
0
Taoyuan County
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Warwickshire
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Wiltshire
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Bangor
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Belfast
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Broughshane
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Liverpool
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Newtonabbey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
As part of the ZOSTER-006 and ZOSTER-022 pivotal trials of the HZ/su vaccine, all study participants completed quality of life (QoL) questionnaires. The only questionnaires encoded into the data base were those from participants who developed a suspected shingles episode during the study. The purpose of this study is to allow for the encoding and analysis of questionnaires for all subjects enrolled in ZOSTER-006 and ZOSTER-022. The aim is to assess the baseline frailty of subjects enrolled in these studies and to investigate whether this population is representative of the general population.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03563183
Query!
Trial related presentations / publications
Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, Schuind AE, Andrew MK; Zoster-064 Study Group. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. J Am Geriatr Soc. 2021 Mar;69(3):744-752. doi: 10.1111/jgs.16917. Epub 2020 Nov 16.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/83/NCT03563183/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/83/NCT03563183/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT03563183
Download to PDF